GO:0047192 1-alkylglycerophosphocholine O-acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047192 describes the enzymatic activity that converts 1-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) to 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) using acetyl-CoA as the acetyl donor.
• This activity is a key step in the remodeling pathway for platelet-activating factor (PAF) biosynthesis, a potent lipid mediator of inflammation and thrombosis.
• The enzyme is often referred to as lyso-PAF acetyltransferase (lysoPAF AT) or PAF-synthesizing enzyme, and its activity can be measured in cell and tissue lysates.
• Altered lyso-PAF acetyltransferase activity has been observed in models of cerebral ischemia and in endothelial cells stimulated by bacterial porins.
• Flavonoids and other small molecules can inhibit this activity, suggesting pharmacological relevance.
• Studying GO:0047192 requires combining enzymatic assays, lipidomics, and CRISPR-based gene editing to link specific genes to PAF production.
Description
1-alkylglycerophosphocholine O-acetyltransferase activity (GO:0047192) is a molecular function that catalyzes the transfer of an acetyl group from acetyl-CoA to the sn-2 position of 1-alkyl-sn-glycero-3-phosphocholine, yielding 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and CoA. This reaction is a central step in the remodeling pathway of PAF biosynthesis, which is critical for the production of a potent phospholipid mediator involved in inflammation, allergy, and thrombosis. Because PAF is not stored in large amounts but synthesized on demand, the regulation of this enzymatic activity directly influences the availability of PAF in response to physiological and pathological stimuli. Researchers study GO:0047192 to understand how cells control lipid mediator production, and to identify therapeutic targets for inflammatory and cardiovascular diseases.
1-alkylglycerophosphocholine O-acetyltransferase activity At A Glance
| GO ID | GO:0047192 |
|---|---|
| GO term | 1-alkylglycerophosphocholine O-acetyltransferase activity |
| Ontology | molecular_function |
| Synonym | lyso-PAF acetyltransferase activity; acetyl-CoA:lyso-PAF acetyltransferase; PAF-synthesizing enzyme; 1-alkyl-2-lysolecithin acetyltransferase |
| Major function | Catalyzes the acetylation of lyso-PAF to form platelet-activating factor (PAF) using acetyl-CoA |
| Reaction | 1-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA |
| Substrates | 1-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) and acetyl-CoA |
| Products | 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) and CoA |
| Pathway | Remodeling pathway of PAF biosynthesis |
| Cofactors | None known; acetyl-CoA serves as the acetyl donor |
What Is GO:0047192?
According to the Gene Ontology, GO:0047192 is defined as the catalysis of the reaction: 1-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA. In simpler terms, it is an acetyltransferase that adds an acetyl group to lyso-PAF to form PAF. This activity is synonymous with lyso-PAF acetyltransferase, acetyl-CoA:lyso-PAF acetyltransferase, and PAF-synthesizing enzyme, among other names.
Why Is 1-alkylglycerophosphocholine O-acetyltransferase activity Important in Cell Biology?
GO:0047192 is important because it governs the final step in the remodeling pathway for PAF synthesis, a lipid mediator that acts at nanomolar concentrations to trigger platelet aggregation, leukocyte activation, and vascular permeability. Dysregulated PAF production is implicated in inflammatory diseases, sepsis, and ischemia-reperfusion injury, making this enzymatic activity a potential target for therapeutic intervention. Moreover, measuring lyso-PAF acetyltransferase activity is a standard approach to assess PAF biosynthetic capacity in cells and tissues.
• Critical for PAF biosynthesis via the remodeling pathway.
• Regulates inflammatory and thrombotic responses.
• Altered activity in cerebral ischemia models.
• Target of natural inhibitors such as flavonoids.
• Measured as a key enzyme activity in PAF metabolism studies.
• Links lipid metabolism to cell signaling.
• Potential biomarker for inflammatory conditions.
• Enables production of PAF on demand in activated cells.
• Provides a druggable step for anti-inflammatory strategies.
• Requires acetyl-CoA, connecting to cellular energy metabolism.
What Happens During 1-alkylglycerophosphocholine O-acetyltransferase activity?
Substrate Binding and Acetyl Transfer
In simple terms: The enzyme grabs lyso-PAF and acetyl-CoA, then moves the acetyl group onto lyso-PAF.
The enzymatic activity begins with the binding of 1-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) and acetyl-CoA to the active site. The enzyme catalyzes the transfer of the acetyl group from acetyl-CoA to the sn-2 hydroxyl of lyso-PAF, forming PAF and releasing CoA. This reaction is highly specific for the alkyl-linked substrate and uses acetyl-CoA as the preferred acyl donor.
Role in the Remodeling Pathway
In simple terms: This is the last step in one of the two main ways cells make PAF.
In the remodeling pathway, PAF is synthesized from a pre-existing membrane phospholipid. The precursor 1-alkyl-2-acyl-sn-glycero-3-phosphocholine is first deacylated by phospholipase A2 to yield lyso-PAF, which is then acetylated by GO:0047192 activity to produce PAF. This two-step process allows rapid PAF production upon cell activation without de novo synthesis.
Tissue and Cellular Distribution
In simple terms: This enzyme activity is found in many cell types, especially those involved in inflammation.
Lyso-PAF acetyltransferase activity has been detected in a variety of cells and tissues, including endothelial cells, platelets, leukocytes, and brain tissue. In cultured human endothelial cells, bacterial porins stimulate PAF biosynthesis, indicating that this activity can be upregulated by microbial products. In the gerbil model of cerebral ischemia, changes in the activities of enzymes in PAF biosynthetic pathways, including this acetyltransferase, have been observed.
Assay and Detection
In simple terms: Scientists measure this activity by mixing cell extracts with lyso-PAF and acetyl-CoA, then detecting the PAF formed.
The activity is typically assayed by incubating cell or tissue homogenates with lyso-PAF and radiolabeled or unlabeled acetyl-CoA, followed by extraction and quantification of the produced PAF using thin-layer chromatography, HPLC, or mass spectrometry. This method has been used to measure key enzyme activities involved in PAF metabolism, including lyso-PAF acetyltransferase.
Key Genes Involved in GO:0047192 1-alkylglycerophosphocholine O-acetyltransferase activity
The following genes and proteins are associated with 1-alkylglycerophosphocholine O-acetyltransferase activity or related PAF biosynthetic pathways, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LYCAT (LPCAT2) | Lyso-PAF acetyltransferase; catalyzes PAF synthesis | Main enzyme for GO:0047192 activity; target for inflammatory studies |
| PLA2G4A | Phospholipase A2; produces lyso-PAF from alkyl-acyl-GPC | Upstream of GO:0047192 in remodeling pathway |
| PAFAH1B1 | PAF acetylhydrolase; degrades PAF | Regulates PAF levels; counteracts GO:0047192 |
| PAFAH2 | PAF acetylhydrolase 2; plasma form | Controls systemic PAF; relevant to inflammation |
| CHAT | Choline acetyltransferase; unrelated but similar name | Potential confusion in literature; not GO:0047192 |
| LPCAT1 | Lysophosphatidylcholine acyltransferase 1 | May have overlapping substrate specificity |
| LPCAT3 | Lysophosphatidylcholine acyltransferase 3 | Involved in lipid remodeling; potential cross-talk |
| PLA2G7 | Lipoprotein-associated phospholipase A2 | Degrades PAF; linked to cardiovascular risk |
| PTAFR | PAF receptor | Mediates PAF signaling; downstream of GO:0047192 |
| NFKB1 | Transcription factor; regulates inflammatory genes | May control expression of PAF biosynthetic enzymes |
| MAPK1 | Mitogen-activated protein kinase 1 | Signaling upstream of PAF production |
| MAPK3 | Mitogen-activated protein kinase 3 | Signaling upstream of PAF production |
| PRKCA | Protein kinase C alpha | Regulates PAF synthesis in activated cells |
| SRC | Proto-oncogene tyrosine-protein kinase Src | May modulate PAF production |
| TNF | Tumor necrosis factor | Cytokine that can induce PAF synthesis |
| IL1B | Interleukin 1 beta | Cytokine that can induce PAF synthesis |
| CXCL8 | Interleukin-8 | Chemokine linked to PAF-mediated inflammation |
| ICAM1 | Intercellular adhesion molecule 1 | Adhesion molecule upregulated by PAF |
How Is 1-alkylglycerophosphocholine O-acetyltransferase activity Regulated?
The activity of 1-alkylglycerophosphocholine O-acetyltransferase is regulated at multiple levels. Inflammatory stimuli such as bacterial porins or cytokines can rapidly increase lyso-PAF acetyltransferase activity in endothelial cells, leading to enhanced PAF production. In cerebral ischemia, the activity of this enzyme changes in a time-dependent manner, suggesting regulation by ischemic stress pathways. Additionally, flavonoids have been shown to inhibit lyso-PAF acetyltransferase activity, indicating that small molecules can modulate this enzyme. The enzyme requires acetyl-CoA, linking its activity to cellular acetyl-CoA availability and energy metabolism.
1-alkylglycerophosphocholine O-acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LYCAT (LPCAT2) | Inflammatory diseases, sepsis | LPCAT2 knockout mice; LPS-induced inflammation |
| PLA2G4A | Cerebral ischemia, neuroinflammation | Middle cerebral artery occlusion in rodents |
| PAFAH1B1 | PAF-related disorders, brain development | PAFAH1B1 knockout mice; neuronal cultures |
| PTAFR | Allergy, anaphylaxis | PTAFR knockout mice; passive cutaneous anaphylaxis |
| PLA2G7 | Cardiovascular disease | PLA2G7 transgenic mice; atherosclerosis models |
Inflammation and Sepsis
PAF is a potent mediator of inflammation, and excessive production via GO:0047192 activity contributes to inflammatory diseases. Bacterial porins stimulate PAF biosynthesis in endothelial cells, implicating this activity in host response to Gram-negative infections. Inhibitors of lyso-PAF acetyltransferase, such as flavonoids, reduce PAF production and may attenuate inflammation.
Cerebral Ischemia and Neurodegeneration
In a gerbil model of cerebral ischemia, the activities of enzymes in PAF biosynthetic pathways, including lyso-PAF acetyltransferase, are altered, suggesting a role in ischemic brain injury. PAF contributes to neuronal damage and neuroinflammation, making this activity a potential target for neuroprotective strategies.
Cardiovascular Disease
PAF promotes platelet aggregation and thrombosis, and its synthesis via GO:0047192 activity is relevant to cardiovascular pathology. Elevated PAF levels have been associated with atherosclerosis and myocardial infarction, and modulating this activity could influence disease progression.
From 1-alkylglycerophosphocholine O-acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LPCAT2 mediate lyso-PAF acetyltransferase activity? | LPCAT2 knockout cell line (e.g., HEK293 or endothelial cells) |
| What is the catalytic mechanism of LPCAT2? | Point mutations in predicted active site residues; recombinant protein assays |
| Can we tag endogenous LPCAT2 for localization studies? | Knock-in of fluorescent tag (e.g., GFP) at LPCAT2 locus |
| Does overexpression of LPCAT2 increase PAF production? | LPCAT2 overexpression in cultured cells; lipidomics |
| Which genes regulate PAF synthesis in inflammation? | CRISPR library screening in macrophage cell lines |
| How does LPCAT2 activity change in ischemia? | In vivo ischemia models with LPCAT2 KO or conditional KO |
How to Study the 1-alkylglycerophosphocholine O-acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lyso-PAF acetyltransferase assay | Enzymatic activity of GO:0047192 | Cell and tissue lysates; inhibitor testing |
| Mass spectrometry lipidomics | PAF and related lipid levels | Profiling PAF production in cells |
| CRISPR-Cas9 knockout | Loss-of-function of candidate genes | Validating LPCAT2 as the main enzyme |
| CRISPR point mutation | Specific amino acid function | Active site mapping |
| Knock-in tagging | Protein localization and interactions | Imaging studies |
| Overexpression | Gain-of-function effects | Testing sufficiency of LPCAT2 |
| RNA-seq | Transcriptional changes | Identifying regulators of PAF pathway |
| Western blot | Protein expression levels | Validating knockout or overexpression |
Enzymatic Activity Assays
Lyso-PAF acetyltransferase activity is measured by incubating cell or tissue lysates with lyso-PAF and acetyl-CoA, followed by quantification of PAF using thin-layer chromatography, HPLC, or mass spectrometry. This direct assay is the gold standard for assessing GO:0047192 activity.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics allows comprehensive profiling of PAF and related phospholipids in biological samples, providing insights into the flux through the remodeling pathway and the contribution of GO:0047192.
CRISPR-Cas9 Gene Editing
CRISPR-Cas9 can be used to generate knockout, point mutation, or knock-in models to study the function of genes encoding lyso-PAF acetyltransferase or related enzymes. These models help establish causal links between specific genes and PAF production.
Expression Analysis
Quantitative PCR, RNA-seq, and Western blotting are used to measure expression levels of LPCAT2 and other PAF pathway genes under different conditions, such as inflammation or ischemia.
How CRISPR Can Be Used to Study GO:0047192 1-alkylglycerophosphocholine O-acetyltransferase activity
Knockout
CRISPR knockout of LPCAT2 (the gene encoding lyso-PAF acetyltransferase) can abolish GO:0047192 activity, providing definitive evidence for its role in PAF biosynthesis. Such models are useful to study the contribution of this activity to inflammation and thrombosis.
Point Mutation
Introducing point mutations in the catalytic residues of LPCAT2 can help dissect the enzymatic mechanism and identify essential amino acids for acetyl transfer. This approach is valuable for understanding substrate specificity and catalysis.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous LPCAT2 locus allows real-time visualization of the enzyme and its subcellular localization, aiding in the study of its regulation and trafficking.
Overexpression
Overexpression of LPCAT2 in cultured cells can increase PAF production, demonstrating sufficiency of the enzyme for GO:0047192 activity. This model is useful for screening inhibitors and studying downstream effects of PAF.
How EDITGENE Supports 1-alkylglycerophosphocholine O-acetyltransferase activity Research
Researchers studying 1-alkylglycerophosphocholine O-acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in PAF production or inflammatory responses. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for 1-alkylglycerophosphocholine O-acetyltransferase activity research.
Frequently Asked Questions About 1-alkylglycerophosphocholine O-acetyltransferase activity
What is 1-alkylglycerophosphocholine O-acetyltransferase activity?
It is an enzymatic activity (GO:0047192) that transfers an acetyl group from acetyl-CoA to lyso-PAF, forming platelet-activating factor (PAF).
What genes are involved in 1-alkylglycerophosphocholine O-acetyltransferase activity?
The main gene is LPCAT2 (also known as LYCAT), which encodes lyso-PAF acetyltransferase. Other genes in the pathway include PLA2G4A and PAFAH1B1.
What is the role of GO:0047192 in inflammation?
This activity produces PAF, a potent inflammatory mediator. Increased activity leads to enhanced PAF synthesis, contributing to inflammation and thrombosis.
How is 1-alkylglycerophosphocholine O-acetyltransferase activity measured?
It is typically measured by incubating cell lysates with lyso-PAF and acetyl-CoA, then quantifying the PAF produced using chromatography or mass spectrometry.
Can flavonoids inhibit 1-alkylglycerophosphocholine O-acetyltransferase activity?
Yes, certain flavonoids have been shown to inhibit lyso-PAF acetyltransferase activity in vitro.
What diseases are associated with 1-alkylglycerophosphocholine O-acetyltransferase activity?
It has been linked to inflammatory diseases, cerebral ischemia, and cardiovascular conditions due to its role in PAF production.
What is the difference between lyso-PAF acetyltransferase and PAF acetylhydrolase?
Lyso-PAF acetyltransferase (GO:0047192) synthesizes PAF by acetylation, while PAF acetylhydrolase degrades PAF by removing the acetyl group.
How can CRISPR be used to study 1-alkylglycerophosphocholine O-acetyltransferase activity?
CRISPR knockout of LPCAT2 can abolish the activity, while knock-in and point mutations can reveal its regulation and catalytic mechanism.
Is 1-alkylglycerophosphocholine O-acetyltransferase activity present in all cell types?
It is found in many cell types, with high activity in endothelial cells, leukocytes, platelets, and brain tissue.
What is the reaction catalyzed by GO:0047192?
The reaction is: 1-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA.
Conclusion
1-alkylglycerophosphocholine O-acetyltransferase activity (GO:0047192) is a critical enzymatic step in the remodeling pathway of PAF biosynthesis, with profound implications for inflammation, cardiovascular disease, and neuroinflammation. Understanding its regulation and the genes involved, particularly LPCAT2, provides opportunities for therapeutic intervention. Leveraging CRISPR-based models and advanced lipidomics will continue to unravel the precise roles of this activity in health and disease.
References
- 1. Yanoshita R et al.. 1996. Inhibition of lysoPAF acetyltransferase activity by flavonoids.. Inflamm Res 45(11):546-9 PMID: 8951505
- 2. Baker RR. 2000. Lipid acetylation reactions and the metabolism of platelet-activating factor.. Neurochem Res 25(5):677-83 PMID: 10905630
- 3. Tufano MA et al.. 1993. Outer-membrane porins from gram-negative bacteria stimulate platelet-activating-factor biosynthesis by cultured human endothelial cells.. Eur J Biochem 214(3):685-93 PMID: 8391435
- 4. Siegel A et al.. 1996. Activities of enzymes in platelet activating factor biosynthetic pathways in the gerbil model of cerebral ischemia.. Biochem Cell Biol 74(3):347-54 PMID: 8883840
- 5. Snyder F et al.. 1987. Measurement of key enzyme activities involved in the metabolism of platelet activating factor.. Methods Enzymol 141:379-96 PMID: 3037250
